Literature DB >> 11796368

Selection of Streptococcus pneumoniae mutants having reduced susceptibility to moxifloxacin and levofloxacin.

Xinying Li1, Xilin Zhao, Karl Drlica.   

Abstract

With Streptococcus pneumoniae, moxifloxacin was 4- and 10-fold more effective than levofloxacin at restricting selection of resistant mutants and at killing resistant mutants, respectively. The selection frequency for first-step topoisomerase mutants was 1,000 times lower for moxifloxacin than for levofloxacin; this difference was lost when second-step mutants were selected.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11796368      PMCID： PMC127057          DOI： 10.1128/AAC.46.2.522-524.2002

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  23 in total

1.  Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae.

Authors:  J M Blondeau; X Zhao; G Hansen; K Drlica
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

2.  Contributions of the 8-methoxy group of gatifloxacin to resistance selectivity, target preference, and antibacterial activity against Streptococcus pneumoniae.

Authors:  H Fukuda; R Kishii; M Takei; M Hosaka
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

3.  Pharmacokinetics of a once-daily oral dose of moxifloxacin (Bay 12-8039), a new enantiomerically pure 8-methoxy quinolone.

Authors:  J T Sullivan; M Woodruff; J Lettieri; V Agarwal; G J Krol; P T Leese; S Watson; A H Heller
Journal:  Antimicrob Agents Chemother       Date:  1999-11       Impact factor: 5.191

4.  Enhancement of fluoroquinolone activity by C-8 halogen and methoxy moieties: action against a gyrase resistance mutant of Mycobacterium smegmatis and a gyrase-topoisomerase IV double mutant of Staphylococcus aureus.

Authors:  T Lu; X Zhao; X Li; A Drlica-Wagner; J Y Wang; J Domagala; K Drlica
Journal:  Antimicrob Agents Chemother       Date:  2001-10       Impact factor: 5.191

5.  Contribution of topoisomerase IV and DNA gyrase mutations in Streptococcus pneumoniae to resistance to novel fluoroquinolones.

Authors:  E Pestova; R Beyer; N P Cianciotto; G A Noskin; L R Peterson
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

6.  Need for annual surveillance of antimicrobial resistance in Streptococcus pneumoniae in the United States: 2-year longitudinal analysis.

Authors:  D F Sahm; J A Karlowsky; L J Kelly; I A Critchley; M E Jones; C Thornsberry; Y Mauriz; J Kahn
Journal:  Antimicrob Agents Chemother       Date:  2001-04       Impact factor: 5.191

7.  Intracellular targets of moxifloxacin: a comparison with other fluoroquinolones.

Authors:  E Pestova; J J Millichap; G A Noskin; L R Peterson
Journal:  J Antimicrob Chemother       Date:  2000-05       Impact factor: 5.790

Review 8.  Antimicrobial use and the emergence of antimicrobial resistance with Streptococcus pneumoniae in the United States.

Authors:  G V Doern
Journal:  Clin Infect Dis       Date:  2001-09-15       Impact factor: 9.079

9.  Fluoroquinolone-resistant Streptococcus pneumoniae associated with levofloxacin therapy.

Authors:  C Urban; N Rahman; X Zhao; N Mariano; S Segal-Maurer; K Drlica; J J Rahal
Journal:  J Infect Dis       Date:  2001-08-09       Impact factor: 5.226

10.  Escherichia coli K-12 mutants resistant to nalidixic acid: genetic mapping and dominance studies.

Authors:  M W Hane; T H Wood
Journal:  J Bacteriol       Date:  1969-07       Impact factor: 3.490
View more
  31 in total

1.  parC mutation conferring ciprofloxacin resistance in Streptococcus pyogenes BM4513.

Authors:  Rodrigo Alonso; Marc Galimand; Patrice Courvalin
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

2.  Dual targeting of GyrB and ParE by a novel aminobenzimidazole class of antibacterial compounds.

Authors:  Trudy H Grossman; Douglas J Bartels; Steve Mullin; Christian H Gross; Jonathan D Parsons; Yusheng Liao; Anne-Laure Grillot; Dean Stamos; Eric R Olson; Paul S Charifson; Nagraj Mani
Journal:  Antimicrob Agents Chemother       Date:  2006-11-20       Impact factor: 5.191

3.  Quinolone-resistant Haemophilus influenzae: determination of mutant selection window for ciprofloxacin, garenoxacin, levofloxacin, and moxifloxacin.

Authors:  Xinying Li; Noriel Mariano; James J Rahal; Carl M Urban; Karl Drlica
Journal:  Antimicrob Agents Chemother       Date:  2004-11       Impact factor: 5.191

4.  Low correlation between MIC and mutant prevention concentration.

Authors:  Karl Drlica; Xilin Zhao; Joseph M Blondeau; Christine Hesje
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

5.  beta-Lactam MICs correlate poorly with mutant prevention concentrations for clinical isolates of Acinetobacter spp. and Pseudomonas aeruginosa.

Authors:  Juliana Gugel; Andrea Dos Santos Pereira; Antônio C C Pignatari; Ana C Gales
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

6.  Moxifloxacin pharmacokinetic profile and efficacy evaluation in empiric treatment of community-acquired pneumonia.

Authors:  Kristina Öbrink-Hansen; Tore Forsingdal Hardlei; Birgitte Brock; Søren Jensen-Fangel; Marianne Kragh Thomsen; Eskild Petersen; Mads Kreilgaard
Journal:  Antimicrob Agents Chemother       Date:  2015-02-09       Impact factor: 5.191

Review 7.  A unified anti-mutant dosing strategy.

Authors:  Xilin Zhao; Karl Drlica
Journal:  J Antimicrob Chemother       Date:  2008-06-10       Impact factor: 5.790

Review 8.  Treating acute exacerbations of chronic bronchitis and community-acquired pneumonia: how effective are respiratory fluoroquinolones?

Authors:  M Balter; K Weiss
Journal:  Can Fam Physician       Date:  2006-10       Impact factor: 3.275

9.  Comparative study of the mutant prevention concentrations of moxifloxacin, levofloxacin, and gemifloxacin against pneumococci.

Authors:  Kim Credito; Klaudia Kosowska-Shick; Pamela McGhee; Glenn A Pankuch; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2009-12-14       Impact factor: 5.191

10.  Use of gyrase resistance mutants to guide selection of 8-methoxy-quinazoline-2,4-diones.

Authors:  Nadezhda German; Muhammad Malik; Jonathan D Rosen; Karl Drlica; Robert J Kerns
Journal:  Antimicrob Agents Chemother       Date:  2008-09-02       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.